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In the Framingham studies, systemic arterial pulse pressure correlated linearly with
morbidity and mortality. Right ventricular (RV) systolic dysfunction and pulmonary
circulation stiffening result in abnormalities of pulmonary arterial (PA) pulse pressure in
PA hypertension (PAH). We investigated the prognostic potential of PA pulse pressure in 67
patients with PAH diagnosed between January 1996 and March 2004 (33 idiopathic PAH, 34
PAH-connective tissue disease).
The population was arbitrarily divided into tertiles of PA pulse pressure ( ¼ systolicdiastolic
PA pressure) and 5-year mortality was assessed using the Kaplan–Meier method. The extent
of RV systolic dysfunction and pulmonary circulation stiffening within each tertile was
assessed by comparing the mean cardiac index and a (a recently described measure of
pulmonary circulation distensibility) in each. Independent predictors of mortality were
identiﬁed by Cox regression.
Five-year mortality rates in patients with low, intermediate and high pulse pressures were
40 %, 91% and 54%, respectively. Pulse pressure did not independently predict mortality,
but cardiac index, 6-min walk test distance and mixed venous oxygen saturation did. Pulse
pressure correlated with circulation stiffening (a) but did not correlate with cardiac index
which tended to be lower in patients with intermediate pulse pressure and high mortality.
PA pulse pressure correlated with pulmonary circulation stiffening but did not predict
mortality in this study. RV dysfunction provided better prognostic information and probably
explains the higher mortality seen in patients with intermediate pulse pressure.
& 2007 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
211 6327;
.ac.uk (A.J. Peacock).Introduction
Pulmonary arterial hypertension (PAH) is a characterised by
proliferative vascular remodelling within the small resistance
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Table 1 Demographic and clinical data for 67 patients
with pulmonary arterial hypertension.
Characteristic
Demographics
Sex (~:#) 50:17
Age 56 (14)
Clinical data
Systolic PA pressure (mmHg) 78 (22)
Diastolic PA pressure (mmHg) 28 (11)
Mean PA pressure (mmHg) 48 (14)
PVRy (mmHg/l/min) 12 (6)
Cardiac index (l/min/m2) 2.2 (0.6)
Mean right atrial pressure (mmHg) 7 (5)
PA occlusion pressure (mmHg) 9 (4)
PA pulse pressure (mmHg) 50 (15)
Mixed venous oxygen saturation (%) 63 (9)
Six-minute walk test distance (m) 275 (117)
Values are mean(71 SD).
PA: Pulmonary artery.
yPVR: Pulmonary vascular resistance.
K.G. Blyth et al.2496vessels of the lung, a reduction in the recruitability and
distensibility of the pulmonary vascular bed and subsequent
stiffening of the proximal, elastic, pulmonary vasculature in
response to elevated transmural pulmonary arterial pressure
(PAP).
Although elevated mean PAP is essential in the diagnosis
of PAH the prognostic inﬂuence of mean PAP at diagnosis has
proven inconsistent. Several previous studies found no
association between mean PAP and survival,1–3 while others
suggested that a high mean PAP at presentation conferred a
greater risk of early death.4 A single study identiﬁed an
apparently paradoxical association between low baseline
mean PAP and early mortality.5 Novel haemodynamic
variables that provided information on survival in PAH
would, therefore, be useful.
Survival in PAH is known to be largely dependent on right
ventricular (RV) function. The pressure loading conditions of
the RV in PAH are dictated by two individual pressure
components; one constant and one pulsatile. Mean PAP
describes the constant component and reﬂects steady ﬂow
conditions within the distal resistance vessels of the lung.
The pulsatile component, in contrast, reﬂects the combined
effects of RV dysfunction and reduced pulmonary circulation
distensibility,6–8 or stiffening, and can be simply described
by pulmonary arterial pulse pressure (PA pulse pressure).
From animal models of PAH we know that pulmonary
vascular remodelling results in the early return of ‘‘re-
ﬂected’’ pressure waves generated during RV contraction. If
these waves return early enough they will be transmitted to
the still ejecting RV before pulmonary valve closure. The
resulting increase in RV afterload adversely affects RV
systolic function.7 PA pulse pressure, therefore, tends to
increase as PAH progresses. Since recent evidence, including
the Framingham studies have demonstrated a linear
correlation between systemic arterial pulse pressure and
cardiovascular morbidity and mortality9–14 we hypothesised
that increasing PA pulse pressure would predict mortality in
patients diagnosed with PAH. The following study was
performed to test this hypothesis.Methods
Study population
In March 2005 the Scottish Pulmonary Vascular Unit (SPVU)
database was reviewed retrospectively. Sixty-seven pa-
tients, diagnosed with PAH between January 1996 and
February 2004, were identiﬁed. Patients with pulmonary
hypertension due to other causes were excluded. Thirty-
three patients had Idiopathic PAH (IPH); the remainder had
PAH associated with connective tissue disease (PAH-CTD).
Demographic and haemodynamic data for the study popula-
tion are summarised in Table 1. Of the 67 patients studied 3
were NYHA class I, 21 were NYHA class II, 28 were NYHA class
III and 15 were NYHA class IV. All patients underwent right
heart catheterisation15,16 and 6-min walk testing17 using
established techniques and standard diagnostic algorithms
were used to assess all patients.15
Right heart catheterisation was performed using a 7F balloon
tipped, triple lumen thermodilution catheter (Edwards Lifesciences, Irvine, US). All measurements were acquired at rest,
in a supine position, breathing room air.
Data collection
The following variables were recorded for each patient from
these baseline tests: mean pulmonary artery pressure (PAP),
systolic PAP, diastolic PAP, mean right atrial pressure, mixed
venous oxygen saturation, pulmonary artery occlusion
pressure (PAOP), total pulmonary resistance (TPR) and
distance completed at 6-min walk test. PA pulse pressure
was determined in all subjects as systolic PAPdiastolic PAP.
For all subjects alive at the time of the study, survival was
recorded in months from the date of baseline right heart
catheterisation. For those patients who had died, survival
was recorded from date of catheterisation until death.
Statistics
For all variables a normal distribution was veriﬁed using
histograms and Kolmogorov–Smirnov tests. Normally distrib-
uted variables were summarised by mean7one standard
deviation (7SD), non-normally distributed variables were
summarised by median (interquartile range). Correlations
were tested by Pearson’s method (after logarithmic trans-
formation for non-normally distributed variables). Patients
were stratiﬁed into tertiles of PA pulse pressure (low
(p 43mmHg, n ¼ 22), intermediate (44–54mmHg, n ¼ 23)
and high (X 55mmHg, n ¼ 22)). Kaplan–Meier mortality
curves were generated for these tertiles and any inequality
in mortality rate was assessed by log rank testing.
Differences in the risk of death between tertiles were
quantiﬁed by hazard ratios (95% conﬁdence interval). The
extent of RV systolic dysfunction and pulmonary circulation
stiffening within each tertile was assessed by comparing the
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Table 2 Proportion of patients within each PA pulse
pressure tertile prescribed individual therapies for
pulmonary arterial hypertension.
Low
PAPP (%)
Intermediate
PAPP (%)
High
PAPP (%)
Warfarin 91 87 100
IV Epoprostenol 23 17 9
SC Treprostinil 14 22 18
Inhaled Iloprost 18 9 18
Bosentan 27 30 36
Sildenaﬁl 9 26 36
CCBs 27 43 41
Note that cumulative percentages will exceed 100 as multi-
ple therapies were prescribed in most patients.
CCBs: Calcium channel blockers.
Figure 1 Kaplan–Meier mortality curves were generated for
tertiles of pulmonary artery pulse pressure determined in 67
patients with pulmonary arterial hypertension. The highest
mortality was seen in patients with intermediate pulse pressure
(log rank statistic 10.25, p ¼ 0.006).
PA pulse pressure and mortality in PAH 2497mean cardiac index and mean a (a recently described
measure of pulmonary circulation distensibility, see below)
of each. Differences in cardiac index and a were quantiﬁed
by a one-way ANOVA (equal variances not assumed), utilising
Tukey’s HSD test.
Independent predictors of mortality were identiﬁed by
multivariable Cox regression after univariable regression
analysis was performed for each recorded variable. Multi-
variable models were constructed using variables within the
univariable regression analysis with p-values p 0.2 or those
variables that we were particularly interested in studying,
e.g. PA pulse pressure. The most efﬁcient model for survival
was identiﬁed using likelihood ratio testing. A backward
elimination method was employed to eradicate any sup-
pressor effect. All variables in the multivariable analyses
were entered as continuous variables and met the assump-
tions of proportional hazards. Co-variables with a correla-
tion coefﬁcient X 0.8 were tested within separate
regression models to avoid the effects of colinearity. The
inﬂuence of individual predictor variables within survival
models was determined by examining exp (b) (95% con-
ﬁdence interval), interpreted as hazard ratio for death per
unit of the predictor variable. A p-value ofo0.05 was
considered statistically signiﬁcant in all tests. All analyses
were performed using SPSS for Windows 11.5 (Chicago,
USA).
Determination of a
The pulmonary circulation co efﬁcient, a, can be used to
describe pulmonary circulation distensibility in PAH. a can
be determined from a distensible vessel model summarised
below. This model has been described in detail elsewhere.18
Mean PAP ¼ ½ð1þ aPAWPÞ
5 þ 5aTPLCO1=5
a
.
Preliminary in vitro experiments have shown that the
distensibility of isolated human pulmonary vessels, when
described by a, appears (a) a consistent characteristic of all
of component vessels within the pulmonary circulation of a
given individual and (b) independent, within that individual,
of vessel diameter.19
Subsequent authors have demonstrated diminished a in
normal exercising humans under conditions of chronic, but
not acute hypoxia and lower a in elderly subjects compared
with young adults.18 These results are in keeping with the
pulmonary vascular remodelling known to occur in
chronic,20 but not acute hypoxia and age-related pulmonary
vascular stiffening.21
We utilised a mathematical equation solver within the
MATLAB software package (MathWorks Inc., MA, USA) to
determine a values for patients in our study, using the
method of successive iterations. The values necessary
for the computation of a were available in 61/67 patients
(in six patients PA OPs were unavailable or technically
unsatisfactory).
Results
During the study period 29/67 (43%) patients died (19/29
were female). The survival of patients with IPH and PAH-CTDwas similar; median survival, for example, was 44 months
in both groups (log rank p ¼ 0.213). 12/29 patients who
died had IPH. In all of the patients who died, the cause of
death was felt to be related to PAH. The mean follow-up
period for the study population was 26 (7 20) months. The
proportion of patients within each tertile of PA pressure that
received individual therapies for PAH are summarised in
Table 2.
PA pulse pressure was normally distributed in the study
population. Mean PA pulse pressure was 49 (716) mmHg. a
was non-normally distributed. Median a was 0.036
(0.029–0.044). After logarithmic transformation mean log a
was 1.434 (0.132).
Five-year mortality rate was highest in patients with
intermediate pulse pressure (log rank statistic 10.25,
p ¼ 0.006, see Figure 1). Estimated 5-year mortality rates
were 40%, 91% and 54% in patients with low, intermediate
and high pulse pressures, respectively. The hazard ratio
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(44–54mmHg) was over four times that seen in patients with
low pulse pressure (p 43mmHg) (HR 4.4 (1.5–12.2),
p ¼ 0.004). Although 5-year mortality rate appeared higher
in patients with high (54%) vs. low (40%) pulse pressures, the
hazard ratio for death was not signiﬁcantly different
between these groups.
PA pulse pressure correlated linearly with pulmonary
circulation stiffening, indicated by a powerful inverseFigure 3 Mean (7SD) log a, cardiac index and mixed venous oxy
arterial pulse pressure (PA pulse pressure) measured in 67 patients
distensibility, as described by log a, decreased progressively with ea
towards lower cardiac index in patients with intermediate PA pulse p
(c) There was a similar trend towards lower mixed venous oxygen s
difference did not achieve statistical signiﬁcance.
Figure 2 Pulmonary arterial pulse pressure and a were
computed and correlated against each other in 67 patients
with Pulmonary arterial hypertension (r ¼ 0.838, po0.001).correlation with pulse pressure and log a (r ¼ 0.838,
po0.001, see Figure 2). a decreased signiﬁcantly as pulse
pressure rose through the three pulse pressure groups (0.048
(0.039–0.062) in the low group, 0.037 (0.032–0.041) in the
intermediate group and 0.028 (0.027–0.03) in the high
group) (see Figure 3(a)).
We found no correlation, in contrast, between pulse
pressure and cardiac index (r ¼ 0.148, p ¼ 0.24). Mean
cardiac index tend to be lower in patients with intermediate
pulse pressure (mean CI 2.0 (0.6) l/min) than it was in the
high (mean CI 2.2 (0.6) l/min) or low (mean CI 2.4 (0.7)
l/min) pulse pressure groups (see Figure 3(b)). These
differences were replicated when mixed venous oxygen
saturation was substituted for cardiac index as an alter-
native correlate of RV function (see Figure 3(c)), but
in neither case did the differences reach statistical
signiﬁcance.Independent predictors of mortality
Results of the initial univariable analyses are shown in Table
3. In a multivariable Cox regression model, summarised in
Table 4, cardiac index, mixed venous oxygen saturation and
6-min walk test distance provided the best prognostic
information. PA pulse pressure did not add prognostic
information (Exp (b) (95% CI) ¼ 0.999 (0.97–1.028),
p ¼ 0.93).gen saturation were determined for each tertile of pulmonary
with pulmonary arterial hypertension. (a) Pulmonary circulation
ch tertile of increasing PA pulse pressure. (b) There was a trend
ressure. This difference did not achieve statistical signiﬁcance.
aturation in patients with intermediate PA pulse pressure. This
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Table 3 Results of univariable linear regression analysis of clinical & haemodynamic variables against survival in 67 patients
with pulmonary arterial hypertension.
Variable Hazard ratio Low 95%CI High 95%CI p-Value
Systolic PAP (mmHg) 1.006 0.990 1.022 0.469
Diastolic PAP (mmHg) 1.008 0.978 1.039 0.592
Mean PAP (mmHg) 1.008 0.984 1.033 0.513
PVR (mmHg/l/min) y 1.059 1.010 1.110 0.017
Cardiac index (l/min/m2) 0.251 0.110 0.573 0.001
RAPz (mmHg) 1.053 0.969 1.144 0.223
PAOPy (mmHg) 1.036 0.943 1.138 0.459
PA pulse pressure (mmHg) 1.008 0.985 1.031 0.502
MVzO2 saturation (%) 0.938 0.900 0.976 0.002
6MWT distance (m) 0.996 0.992 0.999 0.01
PAP: Pulmonary artery pressure.
yPVR: Pulmonary vascular resistance.
zRAP: Right atrial pressure.
yPAOP: Pulmonary artery occlusion pressure.
zMV: Mixed venous.
6MWT: Six-minute walk test.
Table 4 Multivariable Cox regression analysis in 67 patients with pulmonary arterial hypertension.
Variable Exp (b) Low 95% CI High 95% CI p-Value
Cardiac index (l/min/m2) 0.279 0.102 0.760 0.013
MVO2
 (%) 0.954 0.913 0.997 0.038
6MWTy distance (m) 0.996 0.993 0.999 0.048
MVO2: Mixed venous oxygen saturation.
y6MWT: Six-minute walk test.
PA pulse pressure and mortality in PAH 2499Discussion
In our study, PA pulse pressure correlated linearly with the
degree of pulmonary circulation stiffening (see Figures 2 and
3(a)); however, this was not translated directly into an
increase in mortality. Pulse pressure correlated poorly with
cardiac index and did not predict survival when tested as an
independent value. This poor prognostic performance is
consistent with that of mean PAP in previous studies of
patients with PAH.1–5 Our results reiterate the importance of
cardiac index, mixed venous oxygen saturation and 6-min
walk test distance, which are direct correlates of RV
function and as such, proved the most reliable predictors
of prognosis in our patients as has been shown before.1,3,4,22
In our study, mortality was highest in patients with
intermediate pulse pressure (91%) in whom the risk of death
was over four times that seen in patients with low pulse
pressures. The poor independent prognostic performance of
pulse pressure dictates that prognostic signiﬁcance should
not be attributed to intermediate levels of pulse pressure
per se and can probably be understood by examining the
relationship between pulse pressure and RV function. In our
study we found a trend towards more signiﬁcant RV
dysfunction in the intermediate pulse pressure group, as
deﬁned by cardiac index and mixed venous oxygen satura-
tion in Figures 3(b) and (c). We believe that this RV
dysfunction, which determined survival in our study, islikely to explain the excessive mortality in these patients,
although our results cannot deﬁnitively prove this.
A precedent for this concept that ventricular function
can modify the potential prognostic impact of circulatory
stiffening has recently been reported in patients with renal
failure on haemodialysis 23 and type-2 diabetes mellitus.24 In
these groups, left ventricular dysfunction has been shown to
be responsible for unexpectedly high mortality rates in
patients with low systemic pulse pressures and, therefore,
minimal arterial stiffening. Similar ﬁndings have also been
reported in patients with PAH in whom low mean PAP has
been associated with early mortality and attributed to RV
dysfunction in an earlier study.5
We considered the possibility that the higher mortality of
patients with intermediate pulse pressure might have
reﬂected differences in the treatments given to the groups.
Although there was some variation in the proportions of
patients in each tertile treated with individual therapies, as
shown in Table 2, we believe that any potential confounding
effect of therapy should not be overstated. Only intravenous
Epoprostenol has been shown, in a randomised controlled
trial,25 to improve survival after diagnosis in patients with
PAH, although Warfarin26 and Bosentan27 have been shown
to inﬂuence survival in retrospective survival analyses. All
patients in the current study were treated according to
standardised treatment guidelines based on disease sever-
ity; however, the drugs available for treatment did change
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oral agents such as Bosentan and Sildenaﬁl for use in NYHA
class II and III patients. All NYHA class IV patients would
have been treated with IV Epoprostenol throughout the
study period.
Patients with PAH-CTD are known to have a worse
prognosis than those with IPAH, however, there were equal
numbers of each in the intermediate pulse pressure cohort
and median survival was, in our study, identical for patients
with PAH-CTD and IPH (44 months in each). We have
therefore concluded that this factor cannot explain the
mortality of the intermediate group either.
Conclusion
PA pulse pressure proved a poor independent predictor of
mortality in PAH. We do not, therefore, propose its use in
this way. Instead, our ﬁndings emphasise the complicated
nature of the relationship between PAP components, RV
function and mortality encountered by previous authors of
studies in PAH.1–5 Measurements that integrate information
on pulmonary circulation distensibility and RV function, such
as pulmonary arteriolar capacitance which has recently
been described by Mahapatra and colleagues,28 may provide
better prognostic information in future studies.
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